Ipca Laboratories Limited
IPCALAB
Classement en actions
#3404
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Prix de l'action
$20.02
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$5.08B
Changement (1 jour)
-1.65%
Changement (1 an)
38.46%
Pays
IN
Échange Ipca Laboratories Limited (IPCALAB)
Catégorie
Healthcare
Bénéfices pour Ipca Laboratories Limited (IPCALAB)
Bénéfices en Jun 2026 TTM : $200.02M
Selon les derniers rapports financiers de Ipca Laboratories Limited, les bénéfices actuels de l'entreprise sont de $200.02M. En 2024, l'entreprise a réalisé un bénéfice de $100.31M, une augmentation par rapport à celui de 2023 qui était de $89.11M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Ipca Laboratories Limited de 2005 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $200.02M | 51.54% |
| 2025 | $131.99M | 31.59% |
| 2024 | $100.31M | 12.56% |
| 2023 | $89.11M | -39.31% |
| 2022 | $146.83M | -22.19% |
| 2021 | $188.69M | 92.38% |
| 2020 | $98.08M | 24.63% |
| 2019 | $78.69M | 76.36% |
| 2018 | $44.62M | 10.42% |
| 2017 | $40.41M | 135.71% |
| 2016 | $17.14M | -69.96% |
| 2015 | $57.08M | -45.77% |
| 2014 | $105.26M | 26.12% |
| 2013 | $83.46M | 16.17% |
| 2012 | $71.85M | -6.02% |
| 2011 | $76.45M | 28.95% |
| 2010 | $59.28M | 154.37% |
| 2009 | $23.31M | -46.79% |
| 2008 | $43.80M | 23.03% |
| 2007 | $35.60M | 112.82% |
| 2006 | $16.73M | -22.39% |
| 2005 | $21.55M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 782.18% |
IN
|
